Cargando…

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations. METHODS: Adults with diffuse large B-cell lymphoma (DLBCL) scheduled to receive ≥3 cycles of 2- or 3-weekly CHOP with rituximab (R-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettengell, Ruth, Johnson, Hans E., Lugtenburg, Pieternella J., Silvestre, Antonio Salar, Dührsen, Ulrich, Rossi, Francesca G., Schwenkglenks, Matthias, Bendall, Kate, Szabo, Zsolt, Jaeger, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271211/
https://www.ncbi.nlm.nih.gov/pubmed/22101611
http://dx.doi.org/10.1007/s00520-011-1306-6
_version_ 1782222665224814592
author Pettengell, Ruth
Johnson, Hans E.
Lugtenburg, Pieternella J.
Silvestre, Antonio Salar
Dührsen, Ulrich
Rossi, Francesca G.
Schwenkglenks, Matthias
Bendall, Kate
Szabo, Zsolt
Jaeger, Ulrich
author_facet Pettengell, Ruth
Johnson, Hans E.
Lugtenburg, Pieternella J.
Silvestre, Antonio Salar
Dührsen, Ulrich
Rossi, Francesca G.
Schwenkglenks, Matthias
Bendall, Kate
Szabo, Zsolt
Jaeger, Ulrich
author_sort Pettengell, Ruth
collection PubMed
description PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations. METHODS: Adults with diffuse large B-cell lymphoma (DLBCL) scheduled to receive ≥3 cycles of 2- or 3-weekly CHOP with rituximab (R-CHOP-14/21) were eligible. Primary outcome was incidence of FN. RESULTS: FN data were available for 409 patients receiving R-CHOP-14 and 702 patients receiving R-CHOP-21. FN incidence was R-CHOP-14, 20% (81/409) and R-CHOP-21, 19% (133/702). Rates of primary prophylaxis with granulocyte-colony stimulating factor were R-CHOP-14, 84% (345/409) and R-CHOP-21, 36% (252/702). A large number of patients experienced their first FN episode in cycle 1 (R-CHOP-14, 24/81 [30%]; R-CHOP-21, 63/133 [47%]). Multiple risk factors (≥2) for FN were more frequent in patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 60/81 [74%] versus 179/328 [55%]; R-CHOP-21, 98/133 [74%] versus 339/569 [60%]). A similar trend was observed for unplanned hospitalizations (R-CHOP-14, 63/81 [78%] versus 68/328 [21%]; R-CHOP-21, 105/133 [79%] versus 100/569 [18%]). Achievement of chemotherapy relative dose intensity ≥90% was lower among patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 30/81 [37%] versus 234/328 [71%]; R-CHOP-21, 83/133 [62%] versus 434/569 [76%]). CONCLUSIONS: In patients with DLBCL treated with R-CHOP-14 or R-CHOP-21, patients with an event of FN were more likely to experience suboptimal chemotherapy delivery and increased incidence of unplanned hospitalizations than those without FN. FN-related hospitalizations are likely to impact chemotherapy delivery and to incur substantial costs.
format Online
Article
Text
id pubmed-3271211
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-32712112012-02-17 Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma Pettengell, Ruth Johnson, Hans E. Lugtenburg, Pieternella J. Silvestre, Antonio Salar Dührsen, Ulrich Rossi, Francesca G. Schwenkglenks, Matthias Bendall, Kate Szabo, Zsolt Jaeger, Ulrich Support Care Cancer Short Communication PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations. METHODS: Adults with diffuse large B-cell lymphoma (DLBCL) scheduled to receive ≥3 cycles of 2- or 3-weekly CHOP with rituximab (R-CHOP-14/21) were eligible. Primary outcome was incidence of FN. RESULTS: FN data were available for 409 patients receiving R-CHOP-14 and 702 patients receiving R-CHOP-21. FN incidence was R-CHOP-14, 20% (81/409) and R-CHOP-21, 19% (133/702). Rates of primary prophylaxis with granulocyte-colony stimulating factor were R-CHOP-14, 84% (345/409) and R-CHOP-21, 36% (252/702). A large number of patients experienced their first FN episode in cycle 1 (R-CHOP-14, 24/81 [30%]; R-CHOP-21, 63/133 [47%]). Multiple risk factors (≥2) for FN were more frequent in patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 60/81 [74%] versus 179/328 [55%]; R-CHOP-21, 98/133 [74%] versus 339/569 [60%]). A similar trend was observed for unplanned hospitalizations (R-CHOP-14, 63/81 [78%] versus 68/328 [21%]; R-CHOP-21, 105/133 [79%] versus 100/569 [18%]). Achievement of chemotherapy relative dose intensity ≥90% was lower among patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 30/81 [37%] versus 234/328 [71%]; R-CHOP-21, 83/133 [62%] versus 434/569 [76%]). CONCLUSIONS: In patients with DLBCL treated with R-CHOP-14 or R-CHOP-21, patients with an event of FN were more likely to experience suboptimal chemotherapy delivery and increased incidence of unplanned hospitalizations than those without FN. FN-related hospitalizations are likely to impact chemotherapy delivery and to incur substantial costs. Springer-Verlag 2011-11-20 2012 /pmc/articles/PMC3271211/ /pubmed/22101611 http://dx.doi.org/10.1007/s00520-011-1306-6 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Short Communication
Pettengell, Ruth
Johnson, Hans E.
Lugtenburg, Pieternella J.
Silvestre, Antonio Salar
Dührsen, Ulrich
Rossi, Francesca G.
Schwenkglenks, Matthias
Bendall, Kate
Szabo, Zsolt
Jaeger, Ulrich
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title_full Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title_fullStr Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title_full_unstemmed Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title_short Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
title_sort impact of febrile neutropenia on r-chop chemotherapy delivery and hospitalizations among patients with diffuse large b-cell lymphoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271211/
https://www.ncbi.nlm.nih.gov/pubmed/22101611
http://dx.doi.org/10.1007/s00520-011-1306-6
work_keys_str_mv AT pettengellruth impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT johnsonhanse impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT lugtenburgpieternellaj impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT silvestreantoniosalar impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT duhrsenulrich impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT rossifrancescag impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT schwenkglenksmatthias impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT bendallkate impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT szabozsolt impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma
AT jaegerulrich impactoffebrileneutropeniaonrchopchemotherapydeliveryandhospitalizationsamongpatientswithdiffuselargebcelllymphoma